IBT portfolio company Terns acquired by Merck

Summary by AI BETAClose X

International Biotechnology Trust PLC (IBT) announced that its portfolio company, Terns Pharmaceuticals, has agreed to be acquired by Merck for up to $6.7 billion. Terns Pharmaceuticals, a clinical-stage oncology company with its lead candidate TERN-701 in trials for chronic myeloid leukaemia, represented 3.64% of IBT's Net Asset Value as of March 24th. IBT's initial investment in Terns in March 2025 at approximately $3 per share has yielded a return multiple of approximately 17.7x. The acquisition terms offer Terns shareholders $53 per share in cash, a premium to recent trading prices, and this transaction follows another recent M&A event for an IBT portfolio company, highlighting the ongoing M&A activity in the biotechnology sector.

Disclaimer*

UK 100

Latest directors dealings